Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
10.237 / 17.019
#81889

Re: Farmas USA

Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany Agree to Key Terms for the Licensing Back of All Rights to Evofosfamide to Threshold

 

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/11/16 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced an update on its evofosfamide program including that Threshold and Merck KGaA, Darmstadt, Germany have agreed upon key terms for the licensing back of all rights to evofosfamide to Threshold. The companies have a global license and co-development agreement for evofosfamide, an investigational hypoxia-activated prodrug for the treatment of cancer, which was discovered and initially developed by Threshold.

The decision to return rights to evofosfamide to Threshold follows the unblinding of two Phase 3 clinical trials of evofosfamide (TH-CR-406 and MAESTRO) and a previously unplanned, subsequent interim futility analysis of a Phase 2 clinical trial of evofosfamide in patients with non-squamous non-small cell lung cancer (n-s NSCLC). As previously announced, both Phase 3 trials failed to meet the primary endpoint of demonstrating a statistically significant improvement in overall survival. The results of the MAESTRO trial will be presented at the American Society of Clinical Oncology 2016 Gastrointestinal Cancers Symposium during an oral presentation session scheduled to begin at 2:00 p.m. Pacific Time on Friday, January 22, 2016(Abstract #193).

Following the topline results from the two Phase 3 clinical trials, Threshold and Merck KGaA, Darmstadt, Germany decided to unblind the Phase 2 clinical trial in n-s NSCLC and conduct an interim futility analysis. The Phase 2 trial was designed to enroll 440 patients with advanced n-s NSCLC. A total of 265 patients were enrolled and 112 events (deaths) were reported at the time of the interim analysis. An independent Data Safety Monitoring Board conducted the analysis and concluded that the trial is unlikely to reach its primary endpoint of improving overall survival with statistical significance. As a result, further enrollment in this trial will be closed. Additional findings from the interim analysis indicated that evofosfamide plus pemetrexed demonstrated longer progression-free survival (PFS) associated with a reduction in the risk of progression or death by approximately 30%. No new safety findings were reported. Data for this trial will be finalized and results presented at a future medical meeting.

"We are pleased to have agreed to key terms for the licensing back of all rights to evofosfamide to Threshold and we will share our plans for the future development of evofosfamide once our ongoing analyses of the data from the recently unblinded clinical trials are complete," said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "In parallel, we continue to focus on prosecuting two Phase 2 clinical trials of tarloxotinib, our hypoxia-activated EGFR tyrosine kinase inhibitor, and to assess other strategic options for the company."

#81891

Re: Farmas USA

AMRN

99% enrollment para el R-IT, no está nada mal...

Habla de cash-flow positivo, eso igual es posible para 2017 viendo el ritmo y progresión de ventas de Vascepa. Otro cantar es que tenga beneficios, que lo más probable es que ni de coña para 2017

#81892

Re: Farmas USA

Hay que renovar esa Watchlist!!! CLDX, TGTX, KPTI, OMED, etc Todas con excelente futuro por delante! Y de aquí 2 años pues casi todas cotizando en centavos XDDD

#81895

Re: Farmas USA

Bueno, por si hay suerte para hoy y vemos al gato ... puestas ordenes de venta a precios even de los mete-sacas comprados el pasado jueves. Con recuperar liquidez me conformaria. Y por si hay muuuucha suerte por la conferencia JP Morgan del Miercoles venta del paquete NVAX en 7,5 en even tb para hacer mas liquidez.

Hoy tengo lio, no voy a estar pendiente en sesion. Ahi lo dejo.

edito: la carga en 7 de NVAX ni la toco.